ClinicalTrials.gg
RecruitingNCT06370923IMPERATIVEUpdated May 4, 2025

Harnessing Male Peer Networks to Enhance Engagement With HIV Prevention

An interventional study of Peer Distribution and Community Health Worker Distribution in HIV Infections, sponsored by University of Stellenbosch. Recruiting at 1 site in Zimbabwe. Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-04.

Sponsored by University of Stellenbosch · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years later.
Phase
Not applicable
Study type
Interventional
Enrollment
3,591
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Study summary

Novel strategies are needed to engage men in Sub Saharan Africa (SSA) with HIV testing, treatment and prevention services to drive the epidemic towards elimination. Suboptimal engagement with HIV prevention by men increases their risk of HIV acquisition, and is an important driver of new HIV infections in women. HIV self-testing (HIVST) addresses several key facility-based access barriers and HIVST distribution through leveraging male peer networks for HIV prevention is feasible, acceptable and effective in SSA.

The objective of this project is to use an implementation science approach to establish the impact of HIVST distribution through male social networks, with phone-based support and improved risk perception, on PrEP (Pre-Exposure Prophylaxis) uptake among men in Eastern Zimbabwe. The project will leverage infrastructure and data associated with 20-year programme of HIV surveillance and behavioural research in a well-characterized population cohort hosted by the Manicaland Centre for Public Health Research, Zimbabwe.

The study will utilise a cluster randomised design of 44 clusters (22 Intervention:22 control) comprising on average 81 men in each cluster (total N = 3591) followed for 6 months (giving >80% power to detect a difference in PrEP initiation among men of 2% versus 8.5%). In intervention clusters the investigators will identify initial distributors who will receive an HIVST kit for personal use and HIVST kits to distribute to local peers. These peers can subsequently become distributors, allowing the intervention to propagate through peer networks. A toll-free helpline will provide pre- and post-test support and an SMS (Short Message Service) -based risk assessment will expedite PrEP initiation at the clinic. The study team will conduct a performance (process) evaluation of the intervention. to assess implementation fidelity, causal mechanisms underlying trial effectiveness including how characteristics of peer networks affect outcomes. Results of the study will be used to quantify the population level impacts and cost-effectiveness of male peer to peer HIVST distribution strategies on the uptake of PrEP in HIV hyper-endemic settings using a fully calibrated individual-based mathematical model. The envisaged long-term impact of this research is the development of a generalizable, multicomponent male peer-based HIVST and PrEP uptake model for settings where HIV incidence is high.

Read the detailed description

The study will use a cluster-randomised trial design with clusters based on existing village boundaries, which have been utilised as part of an ongoing population-based HIV surveillance. In some cases, neighbouring villages will be aggregated to give approximately equal numbers of adult men in each cluster.

The study cohort from which participants will be recruited is located in Manicaland province, east Zimbabwe.

The intervention will proceed with the following steps:

i. Potential primary distributors will be identified by the research team following engagement with local key informants, these individuals will be contacted and screened for study enrolment. The desired characteristics of these individuals would be that they are members of their community with strong local networks of peers. If they choose to participate an informed consent procedure will be completed by the fieldworkers.

ii. If enrolled, the distributor will be given a pack containing four HIVST kits, one for their own use and three for distribution within the cluster. The study team will collect basic demographic data (name/age / cell number) for the distributor and the intended recipients. They will also record the unique ID of the pack of kits. Advice will be provided on the correct use and interpretation of the HIVST, the need for post-test confirmatory testing in a health facility and the availability of HIV prevention methods including PrEP.

iii. The distributor will be asked to give the test kits to the intended recipients within a seven-day period.

iv. After seven days the helpdesk will contact the distributor and the intended recipients to ascertain whether kits have been received and used, to collect behavioural HIV risk data for the recipients and encourage attendance at a healthcare facility for a confirmatory test. If they have not yet distributed the test kits, the helpline will follow-up at regular intervals to see if distribution has happened. HIVST recipients will be invited to complete the informed consent over the telephone and be enrolled in the study. Follow-up calls will be made to these individuals if necessary. Recipients will be encouraged to consider becoming distributors and advised on the location of community facilities (shops, pharmacies, hairdressers etc.) from where they can obtain the HIVST packs for distribution. This method of HIVST distribution through community-based hubs has been proven to be successful in studies in other Sub-Saharan African settings. [48] A small incentive of USD1:00 will be transferred electronically to the initial distributor for each kit successfully distributed. Successful distribution to peers is defined as the peer having received the HIVST and has been successfully contacted by the helpline to confirm receipt of the HIVST but does not have to use the HIVST or agree to enrol in the study as a distributor. Names and cell numbers will be collected for intended recipients by the study team and stored confidentially.

v. If the recipient chooses to become a distributor, they will go to the community facility and the owner will check using a real-time database that they are eligible. If they pass this screening, they will be given a pack of three HIVST kits for within cluster distribution. If distributors successfully distribute all three HIVST kits within their clusters, they will have the option to collect a further three HIVST kits (up to a total maximum of six HIVST kits) from the community facility. A small remuneration of USD1:00 will be paid to the facility owner for each pack of kits distributed.

vi. After seven days the helpdesk will contact the second level recipients and steps iv) and v) will be repeated until all kits allocated to a particular community have been distributed.

vii. When participants attend a clinic for confirmatory testing, they will return the referral form which was enclosed with the HIVST kit which has a unique barcode and based on their self-reported HIVST result (unreactive/reactive) be screened for PrEP or ART. The outcome of the screening will be recorded in a tick-box on the label and the packaging deposited in a secure box at the clinic from where it will be collected by the study team.

viii. Referral forms, HIVST kits and HIVST packaging will be returned to the central data processing facility for data entry and an additional USD1:00 remuneration will be paid to each individual attending the clinic and participating in a confirmatory HIV test.

ix. All individuals initiating PrEP or ART will be contacted monthly for six months to provide support and to ascertain whether they are still adhering to/continuing with PrEP/ART.

x. Additionally, we will contact all men who report they are still taking PrEP/ART at the end of the follow-up period in order to obtain a dry blood spot to verify the self-report of adherence. This will be sent for analysis in order to assess the intracellular levels of tenofovir diphosphate (TFV-DP) in red blood cells.

02

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • HIV self test
  • HIV Pre Exposure Prophylaxis
  • Peer Networks
03

In context

HIV Infections

4,734 studies on the registry are indexed under HIV Infections; 244 are open to participants now.

This study's planned enrollment of 3,591 is above the median of 80 across 3,489 interventional studies indexed under HIV Infections.

Browse HIV Infections studies →

Lead sponsor

University of Stellenbosch is the lead sponsor of 34 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Resident in study site
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
3,591 participants (estimated)

Study arms

  • Experimental
    Peer Distribution

    In intervention clusters investigators will identify initial distributors who will receive an HIVST kit for personal use and HIVST kits to distribute to local peers. These peers can subsequently become distributors, allowing the intervention to propagate through peer networks. A toll-free helpline will provide pre- and post-test support and an SMS-based risk assessment will expedite PrEP initiation at the clinic.

    Behavioral: Peer Distribution

  • Active comparator
    Community Health Worker Distribution

    This will be the Standard of Care, HIVST kits distributed by Community health workers in the Control clusters.

    Behavioral: Community Health Worker Distribution

Interventions

  • BehavioralPeer Distribution

    In intervention clusters investigators will identify initial distributors who will receive an HIVST kit for personal use and HIVST kits to distribute to local peers. These peers can subsequently become distributors, allowing the intervention to propagate through peer networks. A toll-free helpline will provide pre- and post-test support and an SMS-based risk assessment will expedite PrEP initiation at the clinic.

  • BehavioralCommunity Health Worker Distribution

    Distribution of HIV self tests by community health workers

06

What researchers measure

Primary outcomes

  1. HIV pre-exposure prophylaxis (PrEP) initiation

    A comparison between the intervention and control arms of the proportions of men aged 18 and above initiating PrEP

    Time frame: Up to 6 months from the start of HIVST distribution in the local intervention clusters

Secondary outcomes

  1. Antiretroviral Therapy initiation

    A comparison between the intervention and control arms of the proportions of men aged 18 and above initiating Antiretroviral therapy

    Time frame: Up to 6 months from the start of HIVST distribution in the local intervention clusters

  2. Antiretroviral Therapy or HIV pre-exposure prophylaxis (PrEP) initiation

    A comparison between the intervention and control arms of the proportions of men aged 18 and above initiating Antiretroviral therapy

    Time frame: Up to 6 months from the start of HIVST distribution in the local intervention clusters

  3. HIV testing

    A comparison between the intervention and control arms of the proportions of men aged 18 and above taking an HIV test in the clinic.

    Time frame: Up to 6 months from the start of HIVST distribution in the local intervention clusters

  4. Confirmed positive HIV test

    A comparison between the intervention and control arms of the proportions of men aged 18 and above taking an HIV test in the clinic who are diagnosed HIV positive.

    Time frame: Up to 6 months from the start of HIVST distribution in the local intervention clusters

  5. HIV testing after the use of an HIV self test

    A comparison between the intervention and control arms of the proportions of men aged 18 and above taking an HIV test in the clinic after using an HIV test in the previous three months.

    Time frame: Up to 6 months from the start of HIVST distribution in the local intervention clusters

  6. Attendance at first PrEP follow-up visit

    A comparison between the intervention and control arms of the proportions of men aged 18 and above initiating PrEP who return for their first follow-up visit.

    Time frame: Up to 8 months from the start of HIVST distribution in the local intervention clusters

  7. Attendance at first ART follow-up visit

    A comparison between the intervention and control arms of the proportions of men aged 18 and above initiating ART who return for their first follow-up visit.

    Time frame: Up to 8 months from the start of HIVST distribution in the local intervention clusters

07

Study locations

1 of 1 sites recruiting
  • BRTI - Manicaland Centre for Public Health Research
    Mutare, Manicaland Province, Zimbabwe
    Recruiting
08

References and documents

Publications

  • Mee P, Otambo W, Skovdal M, Harling G, Pickles M, Dobra A, Hallett T, Barnighausen T, McGowan M, Inghels M, Mandizvidza P, Moorhouse L, Tsenesa B, Maswera R, Dzamatira F, Gregson S, Nyamukapa C, Tanser F. IMPERATIVE: Harnessing male peer networks to enhance engagement with HIV prevention: A large-scale cluster randomised trial to increase HIV self-testing and PrEP uptake among men in Eastern Zimbabwe. Res Sq [Preprint]. 2026 Jun 5:rs.3.rs-9814858. doi: 10.21203/rs.3.rs-9814858/v1. PubMed 42281985 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for May 2028, 43 months after the start.

Of 393 non-industry interventional studies with no phase under HIV Infections, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 45. This study's planned 43 months is above that.

Counting every sponsor, half of 402 studies reached it within 28 months; a quarter within 16 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2024
First posted
Apr 17, 2024
StartActual
Oct 21, 2024
Primary completionEst.
May 31, 2028
CompletionEst.
May 31, 2028
Last update
May 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06370923
Lead sponsor
University of Stellenbosch
Collaborators
Biomedical Research and Training Institute, Zimbabwe, Imperial College London, University of Lincoln, University College London Hospitals, University of Copenhagen, University of Washington, Heidelberg University
Responsible party
Frank Tanser (Professor, University of Stellenbosch) — Principal investigator
First posted
Apr 17, 2024
Start date
Oct 21, 2024
Primary completion
May 31, 2028 (estimated)
Completion
May 31, 2028 (estimated)
Last update
May 4, 2025

Study contacts

Constance Nyamukapa, PhD
Contact
nyamukapaconnie@gmail.com
+263 71 480 4050
Frank Tanser, PhD
principal investigator · University of Stellenbosch

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion